MedPath

A comparative study on the treatment effect of Hytrin alone or Hytrin/Hinechol combined administration to patients with prostatic hyperplasia with lower urinary tract symptoms (LUTS)

Not Applicable
Conditions
Diseases of The genitoruinary system
Registration Number
KCT0005736
Lead Sponsor
Cheongju ST.Mary's Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot yet recruiting
Sex
Male
Target Recruitment
200
Inclusion Criteria

1) Men over 40 years old
2) Those with a total score of 8 or more in the International Prostate Symptom Score (IPSS)
3) Those who voluntarily decide to participate in this study and consent in writing to the subject's consent

Exclusion Criteria

1) Those with hypersensitivity to Hythrin-based drugs (alpha-blocker) and Heinecol-based drugs (cholinergic drugs)
2) Those with clinically significant circulatory diseases (myocardial infarction, heart failure, angina, deep veins, pacemaker use, orthostatic hypotension, uncontrolled hypotension)
3) Those on hemodialysis
4) Those who show persistent oliguria due to renal function abnormalities
5) Patients with moderate hepatic impairment (Child-Pugh grade B)
6) Those who participated in other interventional clinical trials within 6 months of screening
7) Those who have a history of or present malignant tumors, and who are inadequate to participate in the study as judged by the principal investigator or the investigator.
8) Asthma patients, patients with hyperthyroidism
9) Others who are inadequate to participate in the research as judged by theprincipal investigator or the investigator.

Study & Design

Study Type
Interventional Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
International Prostate Symptom Score change
Secondary Outcome Measures
NameTimeMethod
Post-void residual urine change;Maximum flow rate change
© Copyright 2025. All Rights Reserved by MedPath